Body Composition and Metabolism: Research suggests that Ipamorelin positively impacts body composition and metabolism by stimulating GH release, which promotes lipolysis and reduces adipose tissue
What the clinical evidence shows Phase 2 monotherapy trials: cagrilintide alone The Phase 2 clinical trial for cagrilintide monotherapy was published in The Lancet in 2021
Active Ingredient: Epithalon Peptide 10 mg Inactive Ingredients: Lyophilized powder without preservatives 100% legal in Poland for research use only, not for human consumption
Treatment includes topical antifungals, antibacterials, or anti-inflammatories, alongside moisture-wicking agents or barrier products to reduce skin-on-skin friction
Pregnancy and lactation safety has not been established, and use is not recommended in women of reproductive potential without adequate contraception
However, the exact mechanisms and clinical significance of these effects are still being explored
